7Markovic O, Marisavljevic D, Cemerikic V,et al. Proliferative activity of myeloma cells determined by Ki-67 antibody: biological and clinical significance [ J ]. Vojnosanit Pregl,2005, 62(1) :33-38.
8Fabian P, Kren L, Nenutil R. Determination proliferative activity of myeloma cells in histologic material[ J ]. Cesk Patol, 2004,40 ( 2 ) :46-49.
9Pruneri G, Carboni N, Baldini L, et al. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation [ J ]. Hum Pathol, 2003,34 ( 1 ) :41-47.
10Alexandrakis M G,Passam F H,Kyriakou D S,et al. Ki-67 proliferation index:correlation with prognostic parameters and outcome in multiple myeloma[J]. Am J Clin Oncol,2004,27(1):8-13.
5Katzmann J A. Prospectives study of serum protein capil- lary zone eleetrophoresis and immunotyping of monoclonal proteins by immunosutracion [J]. Am J Clin Pathol, 1998,110 : 503-509.
6Serefhanoglu S, Sayinalp N, Haznedaroglu I C, et al. Extr- amedullary plasmacytomas of the thyroid and pericardium as initial presentation of multiple myeloma [ J ]. Ann Hematol, 2008,87 (10) :853-854.
7Petersen S L, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature[J]. Am J Hematol, 1999,62 (4) :228-233.
8Rajkumar S V,Hayman S R,Lacy M Q.Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma[J].Blood,2005,106(13):4050-4053.
9Richardson P G,Sonneveld P,Schuster M W.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[J].N Engl J Med,2005,352(24):2487-2498.
10Jagannath S,Durie B G,Wolf J.Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma[J].Br J Haematol,2005,129(6):776-783.
